Lumida
/TMO
⌘K
Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc

TMO
$609.82USD+1.10%+6.64 today

MARKET CAP

225.5B

P/E (TTM)

33.5x

FWD P/E

DAY RANGE

$606 – $615

52W RANGE

$435
$647

AI Summary

Stalk
StalkMedium

TMO remains in a medium- and long-term uptrend, trading above its 50- and 200-day SMAs but is experiencing a corrective pullback. Short-term weakness is visible as price oscillates around the 9- and 20-day EMAs with RSI near neutral. We defer execution and stalk for a dip into the 9/20 EMA zone (~606–610) or a retest of the rising 50-day SMA (~578) for a higher-probability bullish entry. A decisive break below the 50-day SMA would invalidate the medium-term bullish bias.

  • Q2 revenue $11.99B (+10% YoY) and adjusted EPS $6.03 (+13%)
  • Raised full-year revenue guidance to $47.4–48.1B and EPS to $24.93–25.33
  • Customers cautious as academic/government budgets are unsettled for 2026
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$39.2B$44.9B$42.9B$42.9B$44.6B
YoY %+21.7%+14.5%-4.6%+0.1%+3.9%
P / Sales6.8x4.9x4.9x4.6x4.9x
EV / Sales8.0x5.8x5.9x5.7x6.0x
Gross Profit, Adj.$19.6B$19.0B$17.1B$17.7B$18.2B
YoY %+22.7%-3.4%-9.9%+3.5%+3.0%
Margin %50.1%42.2%39.9%41.3%40.9%
EV / Gross Profit16.0x13.8x14.9x13.7x14.6x
EBITDA, Adj.$12.8B$11.9B$10.7B$10.8B$10.9B
YoY %+25.4%-7.2%-9.8%+0.9%+0.6%
Margin %32.7%26.5%25.0%25.2%24.4%
EV / EBITDA24.5x22.1x23.8x22.4x24.4x
EBIT$10.0B$8.4B$6.9B$7.3B$7.7B
YoY %+28.7%-16.3%-18.3%+7.0%+5.6%
Margin %25.6%18.7%16.0%17.1%17.4%
EV / EBIT31.4x31.3x37.2x33.1x34.3x
Net Income$7.7B$7.0B$6.0B$6.3B$6.7B
YoY %+21.2%-10.0%-13.7%+5.7%+5.8%
Net Margin19.7%15.5%14.0%14.8%15.0%
EPS (GAAP)$19.46$17.63$15.45$16.53$17.74
YoY %+21.9%-9.4%-12.4%+7.0%+7.3%